Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presenta...
October 07 2019 - 07:30AM
Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage
immunotherapy company, today announced that the European Molecular
Biology Organization (EMBO) selected, for a scientific
presentation, the poster: “Combination Of Enlivex’s Allocetra-OTS
Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors”
at EMBO’s 2019 Cell Death in Immunity and Inflammation Workshop, on
October 6-9, 2019, at the Kalimera Kriti Hotel & Village
Resort, in Lasithi, Greece.
Enlivex’s data showed significantly increased duration of
survival and overall survival for study subjects who were treated
with the combination therapy, as compared to stand-alone solid
tumor CAR-T therapy. The results of these preclinical studies
showed that the mechanism of action significantly increased the
anti-tumor macrophage population surrounding the human solid tumor
microenvironment in the subjects who were treated with the
combination therapy.
ALLOCETRATM by Enlivex was designed to provide a novel
immunotherapy mechanism of action that targets
life-threatening clinical indications that are defined as “unmet
medical needs”, including prevention or treatment of
complications associated with bone marrow transplantations (BMT)
and/or hematopoietic stem cell transplantations (HSCT); organ
dysfunction and acute multiple organ failure associated with
sepsis; and enablement of an effective treatment of solid tumors
via immune checkpoint rebalancing.
ABOUT ENLIVEXEnlivex is a clinical stage immunotherapy
company, developing an allogeneic drug pipeline for immune system
rebalancing. Immune system rebalancing is critical for the
treatment of life-threatening immune and inflammatory conditions
which involve an out of control immune system (e.g. Cytokine
Release Syndrome) and for which there are no approved treatments
(unmet medical needs), as well as solid tumors immune-checkpoint
rebalancing. For more information, visit
http://www.enlivex.com.
ABOUT EUROPEAN MOLECULAR BIOLOGY ORGANIZATION EMBO is an
organization of more than 1800 leading researchers that
promotes excellence in the life sciences in Europe and beyond. The
major goals of the organization are to support talented researchers
at all stages of their careers, stimulate the exchange of
scientific information, and help build a research environment where
scientists can achieve their best work.
Safe Harbor Statement: This press release contains
forward-looking statements, which may be identified by words such
as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,”
“believes,” “should,” “would”, “intends,” “estimates,” “suggests,”
“has the potential to” and other words of similar meaning,
including statements regarding expected cash balances, market
opportunities for the results of current clinical studies and
preclinical experiments, the effectiveness of, and market
opportunities for, ALLOCETRATM programs, which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that
forward-looking statements involve risks and uncertainties that may
affect Enlivex’s business and prospects, including the risks that
Enlivex may not succeed in generating any revenues or developing
any commercial products; that the products in development may fail,
may not achieve the expected results or effectiveness and/or may
not generate data that would support the approval or marketing of
these products for the indications being studied or for other
indications; that ongoing studies may not continue to show
substantial or any activity; and other risks and uncertainties that
may cause results to differ materially from those set forth in the
forward-looking statements. The results of clinical trials in
humans may produce results that differ significantly from the
results of clinical and other trials in animals. The results of
early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products
using the ALLOCETRATM product line could also be affected by a
number of other factors, including unexpected safety, efficacy or
manufacturing issues, additional time requirements for data
analyses and decision making, the impact of pharmaceutical industry
regulation, the impact of competitive products and pricing and the
impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors described
above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in
Enlivex’s filings with the Securities and Exchange Commission,
including under the heading “Risk Factors” contained in Enlivex’s
most recently filed Annual Report on Form 20-F. The forward-looking
statements contained in this press release speak only as of the
date the statements were made, and we do not undertake any
obligation to update forward-looking statements, except as required
under applicable law.
ENLIVEX CONTACT: Shachar Shlosberger, CFO Enlivex Therapeutics,
Ltd. shachar@enlivex-pharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2023 to Mar 2024